The TCF3-HLF ALL patient cohort We applied high-throughput sequencing analysis integrating short and large insert size paired-end whole-genome, whole-exome and transcriptome sequencing to a discovery cohort consisting of five diagnostic pre-treatment samples of TCF3-PBX1-positive ALL (samples 1a-5a) and TCF3-HLF-positive ALL (samples 6a-9a and 11a). As nontumor controls we used matched bone marrow samples collected after induction treatment for minimal residual disease (MRD) evaluation (maximum leukemic cell load ≤10 −3 ; samples A full list of authors and affiliations appears at the end of the paper.
TCF3-HLF−positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF−positive and treatment-responsive TCF3-PBX1−positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.
Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options One of the hallmarks of pediatric ALL is the presence of subtypedefining chromosomal translocations that cause gene fusions involving master regulators of hematopoietic development. These initiating lesions often cooperate with specific somatic aberrations, including monoallelic deletions of B cell developmental genes, such as PAX5, IKZF1 and EBF1 (ref. 1) . Other cooperative liaisons are represented by trisomy 21q22 with CRLF2 activation [2] [3] [4] or near-haploid ALL with activation of receptor tyrosine kinase or RAS signaling 5 . RAS pathway mutations appear in high-risk ALL but are often lost with disease progression, which suggests involvement of additional tumorigenic factors 6, 7 . The patterns of recurrent genomic alterations need to be better understood, because apart from tyrosine kinase inhibitor−supplemented treatment of BCR-ABL1−positive ALL, the only proven successful first-line treatment strategies for high-risk ALL are chemotherapy intensification and early allogeneic hematopoietic stem cell transplantation 8 .
The translocation t(1;19) 9 that results in a fusion of the transcriptional activation domain of the B cell developmental transcription factor TCF3 to the DNA-binding domain of PBX1 occurs in about 5-10% of precursor B cell (pre-B cell) ALL patients and is associated with a median five-year event-free survival probability of 78-85% 10 . In contrast, the translocation t(17;19)(q22;p13), resulting in the fusion gene TCF3-HLF, defines a rare subtype of ALL (<1% of pediatric ALL) that is typically associated with relapse and death within two years from diagnosis 11, 12 . Both translocations disrupt one allele of TCF3, which drives the B cell differentiation program upstream of the transcription factor PAX5 (ref. 13) . As an initiating event, expression of TCF3-HLF leads to transcriptional reprogramming in pre-leukemic cells. Possible direct targets of TCF3-HLF include the transcription factor gene LMO2, which is implicated in initiation of T cell ALL 14, 15 , and the transcriptional repressor SNAI1 (SLUG), which regulates embryonic development and apoptosis 16, 17 . Further targets have been proposed, including BCL2 (ref. 14) . The TCF3-HLF fusion likely requires additional events to cause leukemia, because TCF3-HLF transgenic and knock-in mice did not recapitulate the human phenotype 18, 19 .
Here we report that the genomic and transcriptomic landscape of TCF3-HLF−positive ALL differs markedly from TCF3-PBX1− positive ALL. The TCF3-HLF fusion likely occurs in B lymphoid progenitors in the context of PAX5 haploinsufficiency and is associated with transcriptional reprogramming toward an immature, hybrid hematopoietic state. Drug response profiling in patient-derived xenografts, which maintained the genomic and global transcriptome landscapes of the corresponding primary leukemic samples, identified resistance patterns to drugs commonly used for the treatment of TCF3-HLF−positive patients. A general trait of TCF3-HLF−positive ALL in our study is extreme sensitivity toward the BCL2-specific inhibitor , indicating new therapeutic options for this fatal ALL subtype.
1b-9b and 11b; Supplementary Table 1 ). For validation, we used additional DNA samples from seven TCF3-HLF-positive cases (diagnostic samples 10a, 12a, 13a, 14a, 15a, 16a, 17a, remission samples 10b, 12b, 13b) and 24 TCF3-PBX1-positive cases ( Supplementary Tables 2 and 3 ). In most cases TCF3-HLF-positive ALL responded to induction chemotherapy but remained MRDpositive. Nine children included in this study died owing to disease progression and treatment-related toxicities within 2 years on average, and only one patient is in remission after a short follow-up time, reflecting the dismal prognosis of TCF3-HLF-positive ALL.
TCF3 breakpoints suggest a committed lymphoid cell of origin
Consistent with previous reports 20, 21 , all TCF3 translocation breakpoints were restricted to three hotspot regions (Fig. 1a,b and Supplementary Fig. 1 ). Those were associated with small nontemplate nucleotide insertions indicative of terminal deoxynucleotide transferase (TdT) activity characteristic of an early B cell stage ( Supplementary Table 4 ). In TCF3, the breakpoints clustered in close proximity to CpG elements in the absence of classical RAG consensus sequence sites ( Supplementary Fig. 1 ), which is a characteristic feature of translocations that occur in lymphoid progenitors at the pro-/pre-B stage. This may represent illegitimate RAG-mediated recombination at cryptic sites, possibly in the context of deaminated CpG nucleotides as proposed for TCF3-PBX1 translocations 22 . Consistent with the idea that TCF3-HLF fusion may occur at a lymphoid-committed rather than a pluripotent progenitor stage, we detected this translocation only in sorted pre-B cell populations containing leukemic cells but neither in stem cells nor in myeloid progenitor cells ( Supplementary Fig. 2 ).
TCF3-HLF ALL and impaired pro-to pre-B cell transition
Pre-B cell ALL is frequently associated with somatic copy number alterations affecting B cell developmental genes. PAX5 deletions are generally observed in 13% of ALL cases and in up to 28% of high-risk ALL 23 . We observed enrichment for monoallelic PAX5 deletions in TCF3-HLF-positive ALL, identifying such events in 67% of the cases ( Fig. 1c and Supplementary Table 2 ). Illegitimate RAG-mediated recombination appears to be implicated in the generation of such events in TCF3-HLF-positive ALL, given the close proximity to RSS motifs ( Supplementary Table 5 ). In most samples without PAX5 deletion, we identified hemi-and homozygous deletions of VPREB1, which encodes a component of the surrogate light chain of the pre-B cell receptor ( Fig. 1c and Supplementary Table 6 ), independent of the lambda light chain locus. VPREB1 deletions in pediatric ALL result in failure to form a viable surrogate light chain in the pre-B cell receptor, an event associated with lower overall survival 24 . In addition, we detected BTG1 gene deletions in three of eight TCF3-HLF-positive cases without PAX5 deletions ( Supplementary Fig. 3a,b) . BTG1 deletions occur frequently in ALL positive for ETV6-RUNX1 (19%) or BCR-ABL1 (26%) and may confer a proliferative advantage 25 . In contrast, we detected no deletion, but only a single PAX5 nonsense mutation in 29 TCF3-PBX1-positive cases ( Fig. 1 and Supplementary Table 3 ). Our results indicate that cooperative genetic events affecting genes regulating the pro-to pre-B cell transition, in particular PAX5, BTG1 and VPREB1, but not IKZF1, are selected in TCF3-HLF-translocated cells. Other deleted genes associated with pre-B cell ALL 26 were JAK2 and CDKN2A/B (patient 7a and 11a) and transcriptional regulators such as ERG, NCOR1, TOX, BACH2, BCL7C, MLLT3, SMARCA2 and MAFK (Fig. 1c) . Translocation:  Diagnosis sample:  PAX5  BTG1  VPREB1  MLL2  ZNF263  HIST1H3A  C6orf89   BACH2   TACC1   NCOR1   BCL7C   MLLT3  SMARCA2   TCF3   DDX3X   TBL1XR1 LEF1 A r t i c l e s Recurrent RAS pathway mutations in TCF3-HLF ALL We identified only a few additional somatic alterations affecting proteincoding sequences in both TCF3-PBX1-and TCF3-HLF-positive ALL ( Fig. 1c , and Supplementary Tables 6 and 7), involving among others, genes associated with pre-B cell ALL 26 (TCF3, PAX5 and LEF1) and transcriptional and chromatin regulation (ZNF263, MLL2, HIST1H3A and C6orf89). We observed a prominent association of TCF3-HLFpositive ALL with activating mutations in RAS signaling pathway genes (NRAS, KRAS and PTPN11), detectable in four of five discovery cases ( Fig. 1c ) and in three of five additional TCF3-HLF-positive validation samples (PTPN11 and SPHK1) (Supplementary Table 2 ). We identified no RAS pathway mutations in the TCF3-PBX1-positive discovery cohort and only one oncogenic NRAS mutation in the 24 TCF3-PBX1positive validation cases ( Supplementary Table 3 ). NRAS and KRAS mutations were generally detected in subclones (Supplementary Table 7 ). We discovered a new fusion gene, KHDRBS1-LCK, due to an interstitial chromosomal deletion in one TCF3-HLF-positive sample (6a), triggering the overexpression of the LCK tyrosine kinase ( Supplementary Fig. 4 ). This was also present in three of 74 randomly selected ALL samples, demonstrating that KHDRBS1-LCK fusion is recurrent in ALL ( Supplementary Fig. 5 ). LCK is a drug target in RAS-dependent cancer cells that have higher LCK expression 27 , suggesting a possible interplay with RAS-related signaling networks in TCF3-HLF-positive ALL. Oncogenic activation of LCK associated with t(1;7)(p34;q34) translocation had been reported in the T cell leukemia cell line HSB2 (ref. 28) . Our data indicate a frequent association of proliferation-driving mutations in TCF3-HLF-positive ALL in the context of stalled B cell differentiation.
Mutations affecting the second TCF3 allele in TCF3-HLF ALL
We identified a mutation in the basic helix-loop-helix region of TCF3 (p.Asp561Val, D561V, Fig. 1c,d) affecting the non-translocated chromosome in one TCF3-HLF-positive case (8a). Mutations at this position have been reported in sporadic Burkitt lymphoma 29 and may reduce binding to its negative regulator ID3 (ref. 29 ). Based on available crystal structure data, p.Asp561Glu may affect the interaction of TCF3 with the transcription factor SCL (also known as TAL1; Fig. 1d ), possibly altering TCF3 protein complexes. We detected a second TCF3 mutation (p.Ser467Gly) in another TCF3-HLF-positive case (13a, Supplementary Table 2 ). The functional consequences of this mutation are currently unclear. We could not detect any somatic mutations in TCF3 by targeted sequencing of 1,033 unselected ALL patients from the European multicenter trial AIEOP-BFM ALL 2000, suggesting a specific association with TCF3-HLF-positive ALL ( Supplementary Table 8 ). Thus, deregulation of normal TCF3 function may also contribute to TCF3-HLF-positive ALL. Corroborating our findings, a recent study included a single TCF3-HLF case, as part of a cohort comparing diagnostic and relapse ALL samples, which showed a PAX5 deletion and two mutations in TCF3 (p.His460Tyr and p.Gly470fs), all of which were conserved at relapse 30 . The relapse sample featured a VPREB1 deletion as well as a shift in subclonal mutations in NRAS (p.Gly12Asp and p.Gly12Val), reinforcing the idea of cooperative effects between TCF3-HLF, and alteration of PAX5 and VPREB1 gene dosage. Taken together, seven of 11 TCF3-HLF cases were hemizygous for PAX5, whereas five samples featured VPREB1 deletions (Supplementary Fig. 6 ).
Reprogramming toward a more immature state in TCF3-HLF ALL Consistent with the occurrence of TCF3-HLF and TCF3-PBX1 translocations in lymphoid precursors, both leukemia subtypes had in common a gene expression signature of B lymphoid cells (including PAX5, BLK, CD19, CD22, CD79B, TCF3, EBF1, VPREB1, RAG1, ROR1, BLNK and DNTT; Supplementary Tables 9 and 10), but differential expression of 401 genes (false discovery rate ≤ 0.001) strongly distinguished Sample: 1a
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Genomic deletion status:
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Patient-derived leukemia cells (P)
Patient treatment a b the two TCF3-translocated subtypes ( Fig. 2a , and Supplementary Tables 11 and 12). In silico prediction of transcription factor binding sites in the corresponding promoter regions revealed enrichment for PBX (Z score = 3.72) and HLF (Z score = 2.99) binding motifs associated with TCF3-PBX1 and TCF3-HLF gene signatures, respectively ( Supplementary Tables 13 and 14) . Further, PBX1 and HLF were the only transcription factors among those with enriched binding motifs that were significantly differentially expressed between the two ALL subtypes, and between leukemia and remission samples. The chimeric HLF transcript was strongly induced in TCF3-HLF, but we detected no wild-type HLF expression. We predicted 39 potential HLF targets, including the known target SNAI2 (SLUG) 16 , GPC4 and BMP3 involved in stem cell proliferation, which showed induced expression in TCF3-HLF samples ( Supplementary Table 15 ). Other potential TCF3-HLF targets that regulate developmental programs and cell survival, such as LMO2 (ref. 14) and BCL2 (ref. 14) , were not predicted. However, their expression was increased in TCF3-HLF-positive ALL.
Gene set enrichment analysis using gene sets from sorted human hematopoietic stem cells and early progenitor populations 31 as well as curated oncogenic (C6) and human immunologic (C7) signatures from MsigDB 32 revealed an enrichment for stem cell and myeloid signatures in TCF3-HLF-positive ALL. In contrast, lymphoid features were more prominent in TCF3-PBX1-positive ALL ( Fig. 2b and Supplementary Table 16 ). The hematopoietic stem cell signature 31 ranked among the top gene sets enriched in TCF3-HLF-positive ALL ( Fig. 2c and Supplementary Table 17 ). We obtained similar results using an independent method based on text mining annotations ( Fig. 2d, and Supplementary Tables 18 and 19) . We also consistently detected high expression of the stem cell marker LGR5 (ref. 33) in TCF3-HLF-positive ALL, suggesting a reactivation of immature features shared with other stem cell populations. Consistent with previous reports, the myeloid marker CD33 was expressed in TCF3-HLF-positive blasts, which provides a target for antibody-directed therapy 12, 34 . Other differentially expressed genes, such as BMP2 (ref. 35) , could present additional therapeutic targets.
Our results are consistent with a model in which TCF3-HLF arises in lymphoid cells and promotes transcriptional reprogramming toward a hybrid hematopoietic state. We also detected features of mesenchyme-derived tissues in TCF3-HLF-positive ALL, which may indicate a profound cellular reprogramming toward a drugresistant state.
Mutation profiles of TCF3-HLF ALL are conserved in xenografts
We generated leukemia xenografts in nonobese diabetic severe combined immunodeficiency (NOD/SCID)/IL2rγ null (NSG) mice for all cases included in this study ( Supplementary Table 20 ) 36, 37 . We also established for the first time to our knowledge leukemia xenografts from follow-up samples with MRD, some with less than 0.1% ALL cells after induction chemotherapy ( Fig. 3a, and Supplementary  Tables 1 and 20) . Leukemia and MRD engraftment was rapid with conserved and predictable kinetics for xenografts derived from the same patient ( Supplementary Fig. 7 ), suggesting that no major adaptation to the mouse microenvironment was needed for proliferation. Most SNVs and intra-chromosomal deletions that had been present at diagnosis were conserved in the corresponding xenografts ( Fig. 3b and Supplementary Table 7 ). Only deletions detected in the relapse sample 11c were not conserved in the corresponding xenografts, and a deletion in BTG1 emerged in one MRD-derived sample (7b, Supplementary Fig. 3c,d) . A few mutations were lost in MRD or relapse xenograft samples, including GNB1 and DDX3X, indicating that these are probably dispensable or may cause drug sensitivity. Mutations in the RAS pathway were largely maintained in xenografts. However, the NRAS mutation p.Gln61His identified in the primary Figure 3 The genomic landscape of TCF3-HLFand TCF3-PBX1-positive ALL is preserved in patient-derived leukemia xenografts. (a) Xenografts were established from cryopreserved patient samples at diagnosis (samples "a"), at follow-up with minimal residual disease (MRD, <1 leukemic cell in 10,000 cells, samples "b") or from disease progression (samples "c") and subjected to whole exome and transcriptome sequencing as well as multiplex ligation-dependent probe amplification (MLPA). All available MRD samples from TCF3-HLF-positive cases were successfully engrafted. (b) Comparison of all transcriptionally expressed nucleotide variations and of selected recurrent deletions frequently found in pediatric ALL in corresponding patient (P) and xenograft (X) samples. Deletions and nucleotide variations are colored according to their frequency in the analyzed leukemic cell population. Deletion frequencies were calculated by integrating whole genome and whole exome sequencing data with MLPA data. Nucleotide variation frequencies were calculated by integrating whole genome, whole exome and transcriptome sequencing data. Recurrently affected genes are indicated by bold symbols. npg A r t i c l e s MRD sample 7b was not detected in the corresponding xenograft. Instead, we identified a heterozygous damaging mutation in KRAS (p.Lys147Glu) associated with Noonan syndrome 38 . In patient 9a, we identified two subclones displaying either a KRAS (p.Gly13Asp) or an NRAS (p.Gly12Ser) mutation. The corresponding xenograft retained only the KRAS mutated subclone. Thus, maintenance and acquisition of RAS pathway mutations in xenografts support the notion that they occur later during selection at a multiclonal level and confer a selective advantage in TCF3-HLF-positive ALL. No other SNVs emerged de novo in the xenografts. In summary, the molecular characteristics of both leukemia subtypes were largely conserved in the xenografts, confirming the validity of this model.
TCF3-HLF−associated gene expression is maintained in xenografts
Hierarchical clustering based on the gene signature specifying the two leukemia subtypes showed that the expression profile and the subtype specificity of the primary leukemia were maintained in the xenografts (Fig. 4) . The genes most significantly upregulated in matched patient and xenograft samples from TCF3-HLF-positive leukemia specified stem cell features (Supplementary Tables 21 and 22) . Similar to the case in patient samples, we detected features of mesenchymederived tissues in xenografts derived from TCF3-HLF-positive ALL. TCF3-HLF-positive leukemias and xenografts displayed systematic downregulation of PAX5 expression to halved levels. Though monoallelic deletions of PAX5 were a prominent feature of TCF3-HLF-positive ALL, we also saw reduced expression in diploid cases, hinting at alternative molecular mechanisms. The recapitulation of this pattern in the xenograft samples enforces the notion that TCF3-HLF-positive leukemia emerges in a specific cellular context with reduced PAX5 expression ( Supplementary Fig. 8) . The essential molecular features of TCF3-HLF-positive samples were maintained in xenografts, providing a useful model of this disease.
Drug activity profiling of TCF3-HLF and TCF3-PBX1 ALL
To determine drug sensitivity and resistance profiles, we established ALL cocultures on human mesenchymal stromal cells under serumfree conditions 39 . Both subtypes depend on stroma for survival ( Supplementary Fig. 9 ). TCF3-PBX1-positive ALL had a higher proportion of cells in S phase than TCF3-HLF-positive ALL on such cultures, reflecting consistent biological differences. By screening 98 bioactive agents, including many agents in clinical development ( Supplementary Table 23 ), on an automated microscopy-based platform, we unambiguously discriminated the two translocations based on their drug sensitivity profiles, using either single (log half maximal inhibitory concentration (IC 50 ), Fig. 5a and Supplementary Fig. 10 ) or multiple response parameters (logIC 50 , log 90% effective concentration (EC 90 ), logEC 50 and area under the curve (AUC), Fig. 5b and Supplementary Table 24 ). To capture informative differences, we compared the responses of xenografts derived from TCF3-HLF-positive ALL to xenografts derived from other high-risk pre-B and T ALL patients on the same platform ( Fig. 5c and Supplementary Table 25 ). This provided information about the activity range of each drug on the respective ALL subtype. TCF3-HLF−positive cases were consistently more resistant to various drugs from the same class, including nucleotide analogs (for example, cytarabine), mitotic spindle inhibitors (for example, vincristine), polo-like and aurora kinase inhibitors. Given the importance of cytarabine and vincristine in standard ALL therapy, the implications of these observations need to be further explored. TCF3-HLF−positive ALL was very resistant to dasatinib in this assay, whereas TCF3-PBX1−positive ALL responded well. This partly challenges a recent report 40 , which had proposed dasatinib as an alternative for the treatment of these leukemias based on strong in vitro activity in one TCF3-HLF-and ten TCF3-PBX1-positive primary ALL samples. However, in vivo studies will be required to verify these differences in drug response, as differences in cell-cycle activity may influence the pattern of response in vitro.
TCF3-HLF−positive ALL were sensitive to glucocorticoids (prednisone and dexamethasone) and to other drugs that could be relevant for the treatment of resistant ALL, including mTOR inhibitors, anthracyclines, bortezomib, the HSP90 inhibitor AUY922 and panobinostat. However, in spite of the good response of patients with TCF3-HLF-positive leukemia to prednisone therapy and the observed responsiveness of TCF3-HLF−positive ALL cells to glucocorticoids and anthracyclines that are commonly used in ALL treatment, patients who undergo this treatment relapse. Our transcriptome data suggested that resistance to apoptosis due to high expression of the anti-apoptotic oncoprotein BCL2 might promote cancer cell survival and constitute a druggable target (Supplementary Fig. 11 ). BCL2 is a putative transcriptional target of TCF3-HLF 14 . Of note, PAX5, commonly deleted in our cohort, normally represses BCL2 transcription 41 .
TCF3-HLF ALL is extremely sensitive to the BCL2 antagonist venetoclax
To assess the role of BCL2 overexpression in TCF3-HLF-positive ALL and to provide preclinical evidence for therapeutic activity, (Fig. 2) shows that xenografts clearly group with their corresponding primary samples. npg we tested the BCL2-targeting drug venetoclax (ABT-199) in our xenograft model (Fig. 5c) . This BH3-mimetic compound is a highly specific small molecule inhibitor that competes with pro-apoptotic BCL2 family proteins for binding to BCL2, and shifts the balance of pro-death and pro-survival signals inside the cell in favor of cell death 42 . Venetoclax is in clinical development (phase II and III trials) for chronic lymphocytic leukemia and lymphoma, and holds promise for ALL and acute myeloid leukemia.
TCF3-HLF−positive ALL samples were more sensitive to venetoclax than TCF3-PBX1-positive samples (Fig. 6a) , which correlated with higher BCL2 transcript and protein expression ( Fig. 6b) . A two-week treatment course of daily venetoclax administration delayed leukemia progression significantly in ALL xenografts from three different TCF3-HLF-positive cases (Fig. 6c,d) . Treatment of mice in the control arm that reached maximal leukemia burden resulted in very rapid reduction of the leukemic load (Fig. 6e) . Xenografts from MRD or relapse remained sensitive to venetoclax ( Supplementary Fig. 11 ). Profiling of primary cells from two additional cases with refractory ALL confirmed exquisite sensitivity to venetoclax (Supplementary Fig. 12 ). Combined treatment of patient-derived xenografts from patients 6-11 with venetoclax and either vincristine or dexamethasone indicated a potentially synergistic effect in some of those patients ( Supplementary Fig. 13 and Supplementary Table 26 ). Our data identified BCL2 dependency in TCF3-HLF ALL as a druggable target, and illustrate how integration of drug response profiling and molecular genetic analyses can inform the development of innovative treatment strategies in patients with unmet therapeutic needs.
DISCUSSION
To our knowledge, a long-term cure has never been achieved for patients with TCF3-HLF-positive ALL. Our study revealed a recurrent pattern of TCF3-HLF accompanied by abnormalities that affect transcriptional regulation of lymphoid development. We found frequent deletions of PAX5 and VPREB1 in association with TCF3-HLF, but did not detect deletions of Ikaros family members, which are commonly affected in ALL 1, 23 . We also uncovered recurrent mutations of the transcription factor TCF3, which acts upstream of PAX5 in (6) *Dexamethasone (7) *Prednisolone (8) Docetaxel (9) Paclitaxel (10) *Vincristine (11) AT9283 (12) Barasertib (13) BI-2536 (14) BX795 (15) RO-3306 (16) Everolimus (17) Temsirolimus (18) Torin-1 (19) *Dasatinib (20) Lestaurtinib (21) XL228 ( 25 ). Boxplots extend from the first to the third quartiles (hinges) of the response range for each compound. Whiskers correspond to values from the hinge to the lowest or highest values within 1.5× of the distance between the first and third quartiles, respectively. Drugs with differential activity include docetaxel, paclitaxel, vincristine, AT9283, barasertib, BI2536, torin-1, dasatinib, lestaurtinib and XL228 (P ≤ 0.05). Drugs which are active across the patients include doxorubicin, idarubicin, mitoxantrone, bortezomib, panobinostat, NVP-AUY922, ABT-199 (venetoclax) and navitoclax. Asterisks indicate drugs currently in clinical use. npg A r t i c l e s lymphoid development, potentially impairing structural interactions with other transcription cofactors 29 . PAX5 expression was reduced by twofold in all TCF3-HLF-positive cases, underscoring the possibility of an interaction between TCF3-HLF, TCF3 and PAX5. PAX5 is required for B lymphoid lineage commitment and maturation 43 , and is frequently deleted in high-risk ALL with complex patterns of copy number abnormalities 23 . Similarly, deletions in IKFZ1, which is required for the development of B and T lymphoid lineages and has additional stem cell-like functions 44 , are detected both in high-risk BCR-ABL1-positive and −negative ALL, and in the more favorable ERG-altered ALL subtype 45 , but never in TCF3-HLF-positive ALL. We also detected focal deletions of VPREB1 in TCF3-HLF ALL, which may lead to a developmental arrest associated with lack of pre-B cell receptor formation and the resulting loss of negative feedback on RAG-mediated recombination 46 . VPREB1 deletions were present at a similar frequency compared to other high-risk ALLs, such as BCR-ABL1-like and BCR-ABL1-positive ALL (~30-40% of cases) 47 or hypodiploid ALL (~30%) 24 , associated with poorer overall survival in high-risk pre-B cell ALL patients 24 . However, specific ALL subtypes associated with good prognosis (for example, ETV6-RUNX1-positive ALL) also present high frequencies of VPREB1 deletions 24 , suggesting an important impact of the genomic context 24 . Thus, distinct patterns of association emerge that are likely to reflect important underlying biological mechanisms. Based on our results, we propose that a reduction of PAX5 gene dosage constitutes a favorable context for the oncogenic activity of TCF3-HLF.
As observed for hypodiploid ALL 5 and in subsets of MLL-rearranged ALL 48 , we identified mutations in NRAS, KRAS and PTPN11 in TCF3-HLF-positive ALL. In our xenograft models we detected variable persistence of NRAS and a switch to KRAS mutations, indicating that RAS mutations are multiclonal and might not be strictly required for disease progression in TC3-HLF-positive ALL. Indeed, mutations in the RAS pathway are enriched at relapse in ALL 7,30,48 but mostly in a subclonal pattern with losses or switches in NRAS and KRAS from diagnosis to relapse. These represent secondary events, possibly compensating functional effects of the initiating events. Mutations in the RAS pathway might not represent optimal therapeutic targets, given their volatility and the potential to select for slower-proliferating, more resistant subclones. The TCF3-HLF gene expression signature, enriched for components of stem cell and myelomonocytic stages, was very similar among leukemias and maintained in xenografts, specifying additional, novel markers associated with stem cell function, such as LGR5, which marks epithelial stem cells 49 and embryonic and fetal hematopoietic progenitor cells in mice 50 . Thus, in analogy to experimental induction of pluripotent stem cells 51, 52 , TCF3-HLF likely induces a whole set of factors that carry out reprogramming and leukemic transformation in the context of low PAX5 expression. Deletion of PAX5 in early B cell progenitors induced dedifferentiation to a state with myeloid and T cell potential 43, 53 . Moreover, rescue with low-level expression of PAX5 in knockout mice generates a stalled biphenotypic B-lymphoid/myeloid state 54 . Together with an activating mutation in STAT5, PAX5 haploinsufficiency initiates ALL in mice 41 . Based on these data, we propose that the initiating TCF3-HLF fusion results in severe transcriptional reprogramming with dedifferentiation. The favorable context for transformation is secured through secondary cooperating lesions in early B cell differentiation genes including TCF3 and PAX5. A central question remains pertaining to the cell of origin in different ALL subtypes. Our study provides important clues that should be further addressed using disease models. The molecular analysis of the TCF3-HLF and TCF3-PBX1 fusion gene breakpoints indicated that the TCF3-HLF, like the TCF-PBX1 translocation, originates in cells already committed to lymphoid differentiation. Furthermore, we found the associated somatic structural variants to be RAG-mediated, which is comparable to patterns identified recently in ETV6-RUNX1positive ALL, the most frequent pre-B cell ALL subtype, which is consistent with expression of RAG in TCF3-HLF-positive ALL 55 . We favor the hypothesis that the TCF3-HLF translocation occurs in a B cell progenitor and that the specific lineage context is constrained further in a restricted developmental stage by additional mutations. The detection of TCF3-HLF being restricted to leukemic cells supports this idea, although initiation in a more immature compartment cannot be formally excluded.
The molecular landscapes of TCF3-HLF-positive ALL were largely conserved in xenografts, providing a valuable, well characterized, model for preclinical testing. Drug activity profiling revealed that TCF3-HLF-positive cases were more resistant to several standard ALL drugs, such as nucleotide analogs (for example, cytarabin) and mitotic spindle inhibitors (for example, vincristine). We detected activity for other relevant drug classes, such as mTOR inhibitors, the proteasome inhibitor bortezomib, the HSP90 inhibitor AUY922 and the HDAC inhibitor panobinostat. The BCL2 inhibitor venetoclax (ABT-199) 42 was highly active in all TCF3-HLF-positive cases analyzed, which we confirmed using primary ALL cells from two additional cases with refractory disease. These results refine data obtained using the broader spectrum BH3 mimetic ABT-737 in TCF3-HLF-positive cell lines 14 . Given the activity of venetoclax also in other ALL subsets including immature T cell ALL (refs. 56,57 and our own unpublished data) and the lack of on-target thrombocytopenia caused by ABT-737, venetoclax should be explored for experimental therapy in refractory ALL in selected cases based on such functional data. Thus integrated genomic and functional analyses of TCF3-HLF-positive ALL provide insight into the molecular context and associated components and offer unprecedented possibilities to investigate new agents for the treatment of these children who currently lack effective therapeutic options.
URLs. Information on the two image processing programs used for in vitro drug screening and automated microscopy can be found at http://acc.ethz.ch/.
METhODS
Methods and any associated references are available in the online version of the paper. Preclinical characterization. Xenograft model. Animal experiments were approved by the veterinary office of the Canton of Zurich, Switzerland. Approval for experiments with human samples in the mouse xenograft model was obtained from the ethics commission of the Canton Zurich (approval number 2014-0383). In brief, primary ALL cells were recovered from cryopreserved samples and transplanted intrafemorally to NSG mice as previously described 36 . Mice were 5−10 weeks old; both males and females were randomly used. Leukemia progression was monitored by flow cytometry with rat antimouse CD45 (eFluor450, clone Immunophenotyping. Immunophenotyping of patient and xenograftamplified human ALL cells after recovery from the spleen was performed as described before 84 . All included xenograft samples consisted of at least 95% human leukemic cells.
Cell culture. Human hTERT immortalized primary bone marrow mesenchymal stromal cells (MSC; provided by D. Campana, St. Jude Children's Research Hospital, Memphis, USA) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS; l-glutamine (2 mM), penicillin/streptomycin (P/S; 100 IU/ml) and hydrocortisone (1 µM). Xenograft-amplified human ALL cells were co-cultured on MSC in AIM V medium (Gibco by Life Technologies) at a ratio of 10:1. All cultured cells were kept in the incubator at 37 °C, 5% CO 2 . For cryopreservation, cells were frozen in heat-inactivated FBS with 10% dimethylsulfoxide and subsequently stored in liquid nitrogen.
Cell viability assay. MSCs were seeded in 24-well plates at a number of 50,000 cells per well in RPMI 1640 medium (10% heat-inactivated FBS). After 24 h primary ALL cells were thawed and seeded as suspension culture alone or in co-culture with MSCs at a number of 400,000 cells per well in AIM-V medium. Three days later, ALL cells were collected from monoculture or co-culture by scraping and stained with 7-AAD (BD Pharmingen). Cell viability (7-AAD negative population) was measured by FACS using counting beads (SPHERO Accu Count Blanc Particles, Spherotech Inc.) for cell counts normalization. Viabilities shown are average viabilities of duplicate wells (normalized to input) and s.d.
Cell cycle assay. MSCs were seeded in 96-well tissue culture plates at a concentration of 10,000 cells per well in 100 µl AIM-V medium. After 24 h ALL cells were added at a concentration of 100,000 cells per well in 90 µl AIM-V. The Click-iTEdU Alexa Fluor 488 Flow Cytometry Assay Kit (Life Technologies) in combination with propidium iodide was used to measure proliferation and to identify the different phases of the cell cycle on days 1 and 3. Co-cultured cells were incubated with EdU (10 µM) for 20 h before cell cycle read-out with flow cytometry. The cell cycle assay was performed in triplicate, and at least two independent experiments were performed for each sample. Similar variances were obtained between the groups that were statistically compared.
In vitro drug screening and automated microscopy. MSCs were seeded in 384well plates at a concentration of 2,500 cells per well in 30 µl AIM-V medium. After 24 h, ALL cells were added at a concentration of 25,000−30,000 cells per well in 27.5 µl AIM-V. Drugs were added as single agents after an additional 24 h using the pipetting robot epMotion 5070 (Eppendorf). Drug response was normalized to ALL cells treated with the drug vehicle alone. Experiments were performed in duplicate in five different dilutions (1, 10, 100, 1,000 and 10,000 nM). For two samples comparable results were obtained in two independent drug screening experiments. After 72 h or 96 h of drug incubation, cells were stained using the CyQUANT direct cell proliferation assay (Life technologies). 20 µl staining mix (AIM V medium, CyQUANT (1:300), repressor (1:20)) was added into each well followed by an incubation time of 1 h at 37 °C, 5% CO 2 . Subsequently, automated imaging was performed using the ImageXpress Micro microscope (Molecular Devices) equipped with a CoolSNAP HQ camera (Photometrics) and a 10× plan fluor objective with 0.3 NA (Nikon). Nine images were taken per well, covering 50% of each well and captured employing the MetaXpress software (Molecular Devices). Images were processed using CellProfiler software (Broad Institute). Cells were classified and counted using the Advanced Cell Classifier software. This software uses random forest classification to assign ALL cells properly.
Immunoblot. Whole cell extracts were prepared from 1 × 10 6 cells using radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA pH 8.0, 0.1% SDS) supplemented with Complete mini protease inhibitor cocktail (Roche Life Science) for 20 min on ice, sonicated as necessary, and diluted with SDS loading buffer (250 mM Tris pH 6.8, 4% SDS, 0.02% bromophenol blue, 40% glycerol, 4% (vol/vol) β-mercaptoethanol). After SDS-PAGE, proteins were blotted onto nitrocellulose membranes. Membranes were blocked in 5% non-fat dry milk and incubated with primary Bcl-2 (clone 124; Dako) and tubulin antibodies diluted 1:1,000 in milk. Horseradish peroxidase−labeled anti-mouse antibodies were used for signal detection with chemiluminescence substrate and direct scanning.
In vivo experiments. ALL cells were recovered from cryopreserved xenograft samples, and per thawed sample 12 to 16 mice were transplanted with 1,000,000 cells per mouse. After three days, randomized cohorts were treated with 100 mg/kg of ABT-199 (ABBVIE) or vehicle control with 6 to 8 mice per treatment arm 85 . ABT-199 or vehicle control were administered orally daily for two weeks. Mice of the ABT-199 group transplanted with sample 7a were additionally treated with a second block (100 mg/kg of ABT-199 for 14 d) starting at day 66, when the frequency of circulating leukemia cells started to increase again. Follow-up of circulating leukemia cells was performed every 7 d by flow cytometry with rat anti-mouse CD45, mouse anti-human CD45, and mouse anti-human CD19; frequency of leukemia cells as ratio of mCD45 -hCD45 + hCD19 + count to total lymphocytes. The investigator was blinded to the group allocation during the assessment of outcome. To evaluate the ability of ABT-199 to decrease tumor burden, four mice in the control group were treated when the frequency of leukemia cells in the peripheral blood was equal or higher than 50%. Follow-up of circulating leukemia cells was performed every 4−7 d. In vivo experiments were terminated when the frequency of circulating leukemia cells reached 50% or earlier if the mice showed abnormal behavior. One in vivo experiment was performed per each sample. 
